Literature DB >> 4856355

Levodopa and melanoma.

A N Lieberman, J L Shupack.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4856355     DOI: 10.1212/wnl.24.4.340

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

1.  The effect of L-dopa, noradrenalin and adrenalin on P-388 mouse leukemia, B-16 mouse melanoma and E 0771 mammary carcinoma.

Authors:  B Shohat; E Kott; B Bornstein
Journal:  Experientia       Date:  1975-01-15

Review 2.  Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

3.  Parkinson's disease, melanoma, and levodopa.

Authors:  J Fermaglich; P Delaney
Journal:  J Neurol       Date:  1977-06-13       Impact factor: 4.849

4.  Levodopa and melanoma: three cases and review of literature.

Authors:  F H Rampen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

5.  High prevalence of malignant melanoma in Israeli patients with Parkinson's disease.

Authors:  R Inzelberg; J M Rabey; E Melamed; R Djaldetti; A Reches; S Badarny; S Hassin-Baer; O Cohen; H Trau; J Aharon-Peretz; R Milo; M Schwartz; M Huberman; L Gilead; M Barchana; I Liphshiz; C Fitzer-Attas; N Giladi
Journal:  J Neural Transm (Vienna)       Date:  2011-02-05       Impact factor: 3.575

6.  Lid melanoma and parkinsonism.

Authors:  S A Haider; V T Thaller
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.